A biopharma company with ties to Imperial College London (ICL) has secured a $226.5M investment to turn biomedical research from UK universities into innovative new therapies for a range of conditions with unmet medical need.
Apollo Therapeutics collaborates with universities and research institutes in the UK to identify research with high therapeutic and commercial potential. ICL is a major partner of Apollo, and its researchers have led development on three of Apollo’s crucial programs, including a novel vaccine for asthma and COPD, a new treatment for acute myeloid leukemia, and biologic inhibitors for the treatment of pulmonary arterial hypertension.
The $226.5M investment comes from Patient Square Capital, bringing Apollo’s total funding since its 2015 launch to over $400 million.
“Apollo’s new funding is great news for pharmaceutical innovation in the UK,” says Simon Hepworth, director of enterprise at Imperial. “It’s also a vote of confidence in Imperial and other UK universities, and reflects the moves we are making to build ever more fruitful partnerships with investors and businesses to accelerate the translation of research breakthroughs into new medical treatments that improve patients’ lives.”
Apollo CEO Richard Mason comments, “Apollo has built a broad and diversified pipeline based on the novel science from our world-leading university partners, focused on major commercial markets, and this latest fund-raising enables us to take our most advanced programs to key clinical value inflection points.”
Source: Imperial College London
